

# RSC Advances

## Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: B. Das and R. R. Parigi, *RSC Adv.*, 2013, DOI: 10.1039/C3RA45419C.



This is an *Accepted Manuscript*, which has been through the RSC Publishing peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, which is prior to technical editing, formatting and proof reading. This free service from RSC Publishing allows authors to make their results available to the community, in citable form, before publication of the edited article. This *Accepted Manuscript* will be replaced by the edited and formatted *Advance Article* as soon as this is available.

To cite this manuscript please use its permanent Digital Object Identifier (DOI®), which is identical for all formats of publication.


More information about *Accepted Manuscripts* can be found in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics contained in the manuscript submitted by the author(s) which may alter content, and that the standard [Terms & Conditions](#) and the [ethical guidelines](#) that apply to the journal are still applicable. In no event shall the RSC be held responsible for any errors or omissions in these *Accepted Manuscript* manuscripts or any consequences arising from the use of any information contained in them.

## GRAPHICAL ABSTRACT

**The first stereoselective total synthesis of a new antitumour and anti-inflammatory neolignan, surinamensinol A**

Parigi Raghavendar Reddy and Biswanath Das\*



Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

## Communication

## The first stereoselective total synthesis of a new antitumour and anti-inflammatory neolignan, surinamensinol A†

Parigi Raghavendar Reddy and Biswanath Das\*


Received (in XXX, XXX) Xth XXXXXXXXX 200X, Accepted Xth XXXXXXXXX 200X

DOI: 10.1039/b000000x

**Abstract:** The stereoselective total synthesis of an antitumour and anti-inflammatory 8-*O*-4'-neolignan, surinamensinol A has been accomplished starting from two aldehydes, 3,4,5-trimethoxy benzaldehyde and vanillin. The key steps involve the asymmetric reduction using a chiral oxazaborolidine complex, Sharpless asymmetric dihydroxylation and Mitsunobu reaction. This is the first report of the total synthesis of surinamensinol A.

## Introduction

Surinamensinol A (**1**) and B (**2**), two new diastereomeric 8-*O*-4'-neolignans along with several other phenolics have recently been isolated from the rhizomes of the aquatic plant, *Acorus gramineus* (Araceae).<sup>1</sup> The first compound bears (7*R*, 8*R*) configuration while the latter (7*S*, 8*R*). The compound **1** and **2** were found to possess potent cytotoxicity against the A549 cell line and moderate activity against SK-OV-3, SK-MEL-2 and HCT-15 cell lines.<sup>1</sup> Both the compounds **1** and **2** also exhibited impressive anti-inflammatory activity. They significantly inhibited NO levels in LPS-stimulated BV-2 cells.<sup>1</sup> In continuation to our work<sup>2</sup> on the construction of natural products herein we disclose the total synthesis of **1**. This is the first report of the synthesis of this molecule. Synthesis of some 8-*O*-4'-oxyneolignan derivatives have been reported,<sup>3</sup> but earlier synthetic approaches were different compared to our present work. Our current approach involves two non-chiral easily available aldehydes as the starting materials. The reagents are also commercially available and the synthetic steps are limited.




Division of Natural Products Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad 500 607, India.

Corresponding author: Fax: +91-40-27193198; E-mail: biswanathdas@yahoo.com (B.Das)


†Electronic supplementary information (ESI) available: Experimental procedures, Copies of <sup>1</sup>H and <sup>13</sup>C NMR spectrum of products. see DOI: 10.1039/b000000x/

The retrosynthetic analysis (Scheme 1) indicates that surinamensinol (**1**) can be synthesized from the chiral diol **3** and the TBS ether **4**. Compounds **3** and **4** can, in turn, be obtained from 3,4,5-trimethoxy benzaldehyde (**5**) and vanillin (**6**) respectively.




Scheme 1. Retrosynthetic route for surinamensinol A

For the synthesis of chiral diol **3**, 3,4,5-trimethoxy benzaldehyde (**5**) was treated with vinyl magnesium bromide to produce the alcohol **7** (Scheme 2).<sup>4</sup> The alcohol **7** was oxidized with IBX and the corresponding ketone was subjected to chiral reduction using (*R*)-(+)-2-methyl-CBS-oxazaborolidine and  $\text{BH}_3\text{SMe}_2$  to furnish the chiral alcohol **8** (*ee* 91%).<sup>5</sup> The free hydroxyl group of **8** was protected as Bn-ether (**9**) by treatment with BnBr and NaH. Compound **9** underwent Sharpless asymmetric dihydroxylation<sup>6</sup> with AD-mix  $\beta$  in *t*-BuOH:H<sub>2</sub>O (1:1) to furnish the diol **10** along with its minor diastereomer (diastereomeric ratio 82:18) which was separated out. The primary hydroxyl group of **10** was tosylated with TsCl to form the mono-hydroxy compound **11**. Subsequent reduction of **11** with  $\text{LiAlH}_4$  afforded the desired fragment **3** in high yield.<sup>7</sup>




**Scheme 2.** Reagents and conditions: (a)  $\text{H}_2\text{C}=\text{CHMgBr}$ , THF,  $0^\circ\text{C}$  to rt, 85%; (b) (i) IBX, DMSO,  $\text{CH}_2\text{Cl}_2$ ,  $0^\circ\text{C}$  to rt; (ii)  $(R)$ -(+)-2-methyl-CBS-oxazaborolidine,  $\text{BH}_3\cdot\text{SMe}_2$ , THF,  $-40^\circ\text{C}$ , 65% (*ee* 91%); (c) NaH, BnBr, THF,  $0^\circ\text{C}$  to rt, 83%; (d) AD-mix  $\beta$ ,  $t$ -BuOH: $\text{H}_2\text{O}$  (1:1),  $0^\circ\text{C}$ , 80% (82:18); (e) TsCl,  $\text{Et}_3\text{N}$ , DCM, DMAP,  $0^\circ\text{C}$  to rt, 76%; (f)  $\text{LiAlH}_4$ , THF,  $0^\circ\text{C}$  to reflux, 89%.

For synthesis of another fragment **4** vanillin (**6**) was subjected to Wittig reaction with  $\text{Ph}_3\text{PCHCOOEt}$  to form the unsaturated ester **12**<sup>8</sup> (Scheme 3) with *E/Z* ratio of 92:8. The reduction of **12** with  $\text{NaBH}_4$  in the presence of  $\text{NiCl}_2\cdot 6\text{H}_2\text{O}$  followed by protection of the phenolic hydroxyl group by treatment with BnBr and NaH and subsequent reduction with  $\text{LiAlH}_4$  afforded the saturated alcohol **13**. The hydroxyl group of **13** was protected as TBS ether (**14**) by using TBSCl and imidazole and the compound **14** was then hydrogenated in the presence of 10% Pd-C to produce the fragment **4**.<sup>9</sup>



**Scheme 3.** Reagents and conditions: (a)  $\text{Ph}_3\text{P}=\text{CHCO}_2\text{Et}$ , benzene, reflux, 81%, (*E/Z* ratio 92:8); (b)  $\text{NaBH}_4$ ,  $\text{NiCl}_2\cdot 6\text{H}_2\text{O}$ , MeOH,  $0^\circ\text{C}$  to rt; (c) NaH, BnBr, THF  $0^\circ\text{C}$  to rt; (d) LAH, dry THF, reflux, 67% (over 3 steps); (e) TBSCl, imidazole, DCM, 95%; (f) 10% Pd-C,  $\text{H}_2$ , EtOAc, rt, 91%.

Finally, the coupling of the two fragments **3** and **4** was carried out by Mitsunobu reaction<sup>10</sup> using  $\text{Ph}_3\text{P}$  and DEAD and the resulting product on treatment with *p*-TsOH in MeOH followed by hydrogenation in the presence of 10% Pd-C yielded the target molecule, surinamensinol A (**1**) (Scheme 4) with 90% *ee*. The physical and spectral properties of the compound were compared to those reported for the natural product.<sup>1</sup>



**Scheme 4.** Reagents and conditions: (a) (i)  $\text{Ph}_3\text{P}$ , DEAD, dry THF, reflux; (ii) *p*-TsOH, MeOH, rt; (iii) 10% Pd-C,  $\text{H}_2$ , rt, 40%.

In conclusion, we have demonstrated the first stereoselective total synthesis of the bioactive neolignan, surinamensinol A starting from two easily available aldehydes, 3,4,5-trimethoxy benzaldehyde and vanillin. Chiral reduction, asymmetric dihydroxylation and Mitsunobu reaction are the key steps in the present synthesis. The overall yield of **1** starting from **5** is 10% involving sixteen steps.

## Acknowledgments

The authors thank CSIR and UGC, New Delhi for financial assistance. They are also thankful to NMR, Mass and IR divisions of CSIR-IICT for spectral recording.

## References

<sup>†</sup>Part 68 in the series, "Synthetic studies on natural products"

1. K. H. Kim, E. Moon, H. K. Kim, J. Y. Oh, S. y. Kim, S. U. Choi, K. R. Lee, *Biorg. Med. Chem. Lett.* **2012**, 22, 6155.
2. (a) G. C. Reddy, P. Balasubramanyam, N. Salvanna, T. S. Reddy, B. Das, *Biorg. Med. Chem. Lett.* **2012**, 22, 2415. (b) Ch. Sudhakar, P. R. Reddy, G. C. Kumar, P. Sujitha, B. Das, *Eur. J. Org. Chem.* **2012**, 1253. (c) D. B. Shinde, B. S. Kanth, M. Srilatha, B. Das, *Synthesis*, **2012**, 469. (d) Ch. R. Reddy, B. Veeranjanyulu, S. Nagendra, B. Das, *Helv. Chem. Acta* **2013**, 96, 505. (e) P. R. Reddy, Ch. Sudhakar, J. N. Kumar, B. Das, *Helv. Chem. Acta* **2013**, 96, 289.
3. (a) C. E. Rye, D. Barker, *European Journal of Medicinal Chemistry*, **2013**, 60, 240. (b) S. Kumar Das, S. Kumar Das, G. Panda, *Eur. J. Org. Chem.* **2010**, 5100. (c) A-L. Lee and S. V. Ley, *Org. Biomol. Chem.* **2003**, 1, 3957. (d) C. Curti, F. Zanardi, L. Battistini, A. Sartori, G. Rassu, L. Pinna and G. Casiraghi, *J. Org. Chem.* **2006**, 71, 8552. (e) M. Nagaraju, R. Chandra, B. B. Gawali, *SYNLETT*, **2012**, 23, 1485.
4. C. Sudhakar, P. R. Reddy, C. G. Kumar, P. Sujitha, B. Das, *Eur. J. Org. Chem.* **2012**, 1253.
5. S. Tamura, A. Shiomi, T. Kimura, N. Murakami, *Biorg. Med. Chem. Lett.* **2010**, 20, 2082.
6. K. B. Sharpless, W. Amberg, Y. L. Bennani, G. A. Crispino,

- J. Hartung, K. S. Jeong, H. L. Kwong, K. Morikawa, Z. M. Wang, *J. Org. Chem.* **1992**, *57*, 2768.
7. H. J. Yuan, Y. Y. Cheng, S. Qian, X. Xiao, Y. Wu, *Chinese Chemical Letters*, **2010**, *21*, 127.
8. B. Das, B. Veeranjanyulu, P. Balasubramanyam, M. Srilatha, *Tetrahedron: Asymmetry* **2010**, *21*, 2762.
9. S. P. Chavan, Ch. Praveen, *Tetrahedron Lett.* **2005**, *46*, 1939.
10. O. Mistunobu, M. Yamada, *Bull. Chem. Soc. Jpn.* **1967**, *40*, 2380.